Metastatic Breast Cancer Market By Drugs 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Metastatic Breast Cancer Market
Metastatic Breast Cancer Market: By Drugs (Paclitaxel, Tamoxifen, Vinblastine, Raloxifene, Docetaxel), By Treatment (Radiation Therapy, Vitamin Therapy, Macrobiotic Diets, Homeopathy, Herbal Medication) & By Region-Forecast (2016-2021)
Report Code : HCR 0340
Updated Date: 04 January, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
1. Metastatic Breast Cancer Market – Market Overview
2. Executive Summary
3. Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
   3.3. Product Benchmarking
   3.4. End User Profiling
   3.5. Top 5 Financials Analysis
4. Metastatic Breast Cancer Market– Market Forces
   4.1. Drivers
      4.1.1. Increasing awareness about breast cancer globally
      4.1.2. Increasing R&D expenditure in oncology field by major players
   4.2. Restraints
      4.2.1. High initial cost for new therapy development
   4.3. Opportunities
      4.3.1. Developing healthcare infrastructure in emerging economies
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Metastatic Breast Cancer Market– Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Metastatic Breast Cancer Market, By Drugs
   6.1. Paclitaxel
   6.2. Tamoxifen
   6.3. Vinblastine
   6.4. Raloxifene
   6.5. Docetaxel
   6.6. Others
7. Metastatic Breast Cancer Market, By Treatment
   7.1. Radiation Therapy
   7.2. Vitamin Therapy
   7.3. Macrobiotic Diets,
   7.4. Homeopathy
   7.5. Herbal Medication
8. Metastatic Breast Cancer Market, By Geography
   8.1. Europe
      8.1.1. Germany
      8.1.2. France
      8.1.3. Italy
      8.1.4. Spain
      8.1.5. Russia
      8.1.6. U.K.
      8.1.7. Rest of Europe
   8.2. Asia Pacific
      8.2.1. China
      8.2.2. India
      8.2.3. Japan
      8.2.4. South Korea
      8.2.5. Rest of Asia-Pacific
   8.3. North America
      8.3.1. U.S.
      8.3.2. Canada
      8.3.3. Mexico
   8.4. Rest of the World (RoW)
      8.4.1. Brazil
      8.4.2. Rest of RoW
9. Metastatic Breast Cancer – Market Entropy
   9.1. Expansion
   9.2. Technological Developments
   9.3. Merger & Acquisitions, and Joint Ventures
   9.4. Supply- Contract
10. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
   10.1. Bayer pharmaceuticals
   10.2. Onyx pharmaceuticals
   10.3. Bristol-Myers Squibb Company
   10.4. GlaxoSmithKline Pharmaceuticals
   10.5. Novartis AG
   10.6. Roche pharmaceuticals
   10.7. Aslan Pharmaceuticals Pte. Ltd.,
   10.8. AstraZeneca Plc
   10.9. Boehringer Ingelheim GmbH
   10.10. Biocon Limited
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
11. Appendix

   11.1. Abbreviations
   11.2. Sources
   11.3. Research Methodology
   11.4. Bibliography
   11.5. Compilation of Expert Insights
   11.6. Disclaimer
Metastatic breast cancer (also called stage IV or advanced breast cancer) in medical terms can be defined as a breast cancer which has spread beyond the breast to other vital organs in the body like bones, lungs, liver or brain are the few most common ones to name. Mostly, metastatic breast cancer arises months or years after a person has completed treatment for early or locally advanced type of cancer i.e. stage I, II or III of breast cancer. Hence metastatic breast cancer is sometimes also called distant recurrence.  Globally increasing awareness and development of new therapies and drugs is expected to drive the demand for metastatic cancer during the period of study.

 Metastatic Breast Cancer Market

Geographically North America dominated global metastatic breast cancer market driven by best in the class healthcare infrastructure, advanced facilities, best healthcare practices, increased awareness about breast cancer and higher spending on healthcare by its citizens. North America was followed by Europe and Asia-Pacific as second and third largest market for metastatic breast cancer market. Asia Pacific is projected to have fastest growth, owing to rapidly increasing healthcare infrastructure, increasing awareness, increased spending, government initiatives and growing medical tourism industry in developing nations such as China, and India in this region.

This report identifies the global metastatic breast cancer market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to global metastatic breast cancer market.

This report segments global metastatic breast cancer market on the basis of drugs, treatment, and regional market as follows:

  • Metastatic Breast Cancer Market, By Drugs: Paclitaxel, Tamoxifen, Vinblastine, Raloxifene, Docetaxel and Others
  • Metastatic Breast Cancer Market, By Treatment: Radiation Therapy,  Vitamin Therapy, Macrobiotic Diets, Homeopathy, Herbal Medication
  • This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

This report identifies all the major companies operating in the metastatic breast cancer market. Some of the major companies’ profiles in detail are as follows:
  • Roche pharmaceuticals
  • Aslan Pharmaceuticals Pte. Ltd.,
  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • Biocon Limited
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports